Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab
| Autor: | Nayana Vora, Michele Kirschenbaum, George Somlo, Paul Frankel, Thehang Luu, Sally Shaw, John H. Yim, Laura Kruper, Jing Zhai, Arvind Manohar Shinde, Courtney Vito, Kim Wai Yu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Paclitaxel Anthracycline Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Triple Negative Breast Neoplasms Antibodies Monoclonal Humanized Inflammatory breast cancer Article Carboplatin chemistry.chemical_compound Trastuzumab Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines skin and connective tissue diseases Neoadjuvant therapy Aged Retrospective Studies Chemotherapy Taxane business.industry General Medicine Middle Aged medicine.disease Neoadjuvant Therapy Receptors Estrogen chemistry Chemotherapy Adjuvant Female Surgery Neoplasm Recurrence Local Receptors Progesterone business medicine.drug |
| Zdroj: | The Breast. 24:18-23 |
| ISSN: | 0960-9776 |
| DOI: | 10.1016/j.breast.2014.10.008 |
| Popis: | Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect